您所在的位置: 首页 --> 导师团队 --> 郭军

导师基本信息

  • 姓名:郭军
  • 性别:
  • 民族:汉族
  • 科室:肾癌黑色素瘤内科
  • 职称:主任医师 ,教授
  • 专业:肿瘤学 、肿瘤内科学
  • E-MAIL: guoj307@126.com

学术论文 | 科研项目 | 招生计划

Yan Kong#, Xinan Sheng#, Xiaowen Wu#, Junya Yan, Meng Ma, Jiayi Yu, Lu Si,Zhihong Chi, Chuanliang Cui, Jie Dai, Yiqian Li, Huan Yu, Tianxiao Xu, Huan Tang,Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xieqiao Yan, Siming Li, and Jun Guo*. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma indicate the potential for CDK4/6 Inhibitors in Targeted Therapy. ,Clinical Cancer Research ,2017;23(22):6946-6957

Bai X#, Kong Y#, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J*, Si L*. MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. ,Clinical cancer research ,2017;23(20):6120-7

Yu J#, Wu X#, Yu H, Li S, Mao L, Chi Z, Si L, Sheng X, Cui C, Dai J, Ma M, Tang H, Xu T, Yan J, Kong Y*, Guo J*. Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon. ,Transl Oncol ,2017;10(5):719-25

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors ,BMC Cancer ,2017;17:16

Lian B, Cui CL, Zhou L, Song X, Zhang XS, Wu D, Si L, Chi ZH, Sheng XN, Mao LL, Wang X, Tang BX, Yan XQ, Kong Y, Dai J, Li SM, Bai X, Zheng N, Balch CM, Guo J*. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. ,Ann Oncol ,2017;28(4):868-873

J. Guo, R. D. Carvajal, R. Dummer, A. Hauschild, A. Daud, B. C. Bastian, S. N. Markovic, P. Queirolo, A. Arance, C. Berking, V. Camargo, D. Herchenhorn, T. M. Petrella, D. Schadendorf, W. Sharfman, A. Testori, S. Novick, S. Hertle, C. Nourry, Q. Chen, F. S. Hodi. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial ,Annals of Oncology ,28: 1380–1387, 2017

Dai J, Wu S, Kong Y, Chi Z, Si L, Sheng X, Cui C, Fang J, Zhang J, Guo J*. Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma. ,Sci Rep ,2017;7:39597

Sheng X, Kong Y, Li Y, Zhang Q, Si L, Cui C, Chi Z, Tang B, Mao L, Lian B, Wang X, Yan X, Li S, Dai J, Guo J*. GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. ,Eur J Cancer ,2016;65:156-63

Sheng X, Kong Y, Li Y, Zhang Q, Si L, Cui C, Chi Z, Tang B, Mao L, Lian B, Wang X, Yan X, Li S, Dai J, Guo J. GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. ,Eur J Cancer ,2016;65:156-63

Agnieszka Malczewski, Andrea Marshal, Miranda J. Payne, Lili Mao, Dimitrios Bafaloukos, Lu Si, Dimitrios Pectasides, George Fountzilas, Jun Guo, Helen Gogas, Mark R. Middleton. Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials ,Cancer Medicine ,2016; 5(1):17–23

Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. ,Oncotarget ,2016;7(19):27044-54

Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. ,Oncotarget ,2016;7(19):27044-54

Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. ,Oncotarget ,2016;7(19):27044-54

Kong Y, Si L, Li Y, Wu X, Xu X, Dai J, Tang H, Ma M, Chi Z, Sheng X, Cui C, Guo J. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors. ,Clin Cancer Res ,2016;22(4):1018-27.

恶性黑色素瘤 , 课题负责人 , 2016.1.1~2018.12.31, 北京市医院管理局扬帆计划重点医学专业/ZYLX201603

ARHGAP21 S1075X基因突变在肢端型黑色素瘤发病中的作用及机制研究 , 课题负责人 , 2017.1.1~2020.12.31, 国家自然科学基金面上项目/81672696

基于驱动基因突变筛选的肢端及粘膜黑色素瘤分子靶向治疗策略 , 课题负责人 , 2015.5.1~2018.5.1, 北京市科委科技计划课题/Z151100003915074

DNA代谢和损伤应答相关蛋白在肿瘤个体化诊治中的应用研究 , 课题负责人 , 2013.1.1~2017.8.31, 国家科技部973计划项目课题 2013CB911004

研究生招生计划
招生年度 招生专业 学位级别 学位类型 研究方向 选拔方式
2021 肿瘤内科学 长学制 专业学位 临床技能训练与研究 长学制二级学科培养
2021 肿瘤内科学 博士 专业学位 临床技能训练与研究 申请考核制
2021 肿瘤内科学 硕士 专业学位 临床技能训练与研究 全国统考
2021 肿瘤学 博士 科学学位 肿瘤免疫治疗 申请考核制

社会任职

  • 国际黑色素瘤基金会(MIF)海外咨询顾问
  • 中国抗癌协会泌尿肿瘤分会常务委员
  • 国际黑色素瘤联盟(Society for Melanoma Research)亚太地区主席
  • 中国临床肿瘤学会(CSCO)肾癌专业委员会主任委员
  • 中国临床肿瘤学会(CSCO)黑色素瘤专业委员会主任委员